Abstract
Prostate cancer (PCa) diagnosis based on patient urine analysis provides non-invasive and promising method as compared to biopsy and a prostate-specific antigen (PSA) test. This study was conceived to investigate whether Integrin alpha V (ITGAV) protein is present in urine and assess the urinary ITGAV diagnostic potential for PCa. Materials and Methods: Urinary ITGAV expression was determined by Western blot analysis and quantified by ELISA in urine from men with PCa (n = 47), benign prostate hyperplasia (n = 42) and age-matched controls (n = 22). Results: The level of ITGAV protein was significantly lower in PCa urine samples as compared to those in the control group (p < 0.00001). The decrease of ITGAV in urine was highly predictive of PCa with 91.5% sensitivity, 91.4% specificity, 0.93 area under the ROC curve, and its specificity was better than that of serum PSA. Conclusion: Urinary ITGAV provides a novel noninvasive biomarker with high specificity.
Highlights
Prostate cancer (PCa) is the primary cause of death in men all over the world, which is associated, in part, with the absence of relevant biomarkers for early diagnosis and treatment
The Integrin alpha V (ITGAV) level was varied in benign prostatic hyperplasia (BPH) samples, a statistically significant decrease was noted in the cancer tissue samples as compared with the BPH tissues (Figures 1C, D)
We showed that ITGAV, the member of the integrin receptor family, is present as a “soluble” protein in the conditioned medium (CM) produced by prostate cancer cells and can be found in first pass urine collected without preceding prostate massage
Summary
Prostate cancer (PCa) is the primary cause of death in men all over the world, which is associated, in part, with the absence of relevant biomarkers for early diagnosis and treatment. The false positive results (PSA > 4 ng/ml) have been observed in patients with benign prostatic hyperplasia (BPH) and prostatitis, while the low serum PSA values (less than 4 ng/ml) have been detected in patients having aggressive cancer with the Gleason score > 7 [1, 2]. These limitations in accuracy in cancer prediction and monitoring require the urgent need of additional biomarkers, which could become a complement of serum PSA
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
